SNV, a lipophilic superactive VIP analog, acts through cGMP to promote neuronal survival

被引：22

作者：

Ashur-Fabian, O

Perl, O

Lilling, G

Fridkin, M

Gozes, I ^{[1
]}

机构：

[1] Tel Aviv Univ, Sackler Sch Med, Dept Clin Biochem, IL-69978 Tel Aviv, Israel

[2] Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel

来源：

PEPTIDES | 1999年 / 20卷 / 05期

关键词：

vasoactive intestinal peptide (VIP); Stearyl-Nle(17)-VIP (SNV); cyclic guanosine monophosphate (cGMP); immunocytochemistry; radioimmunoassays (RIA); enzymeimmunoassays (EIA); neuronal survival;

D O I：

10.1016/S0196-9781(99)00017-0

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The current study explored whether the neuroprotective effects of vasoactive intestinal peptide (VIP) and its analog Stearyl-Nle(17)-VIP (SNV) were mediated through cGMP. SNV, was previously found to be 100-fold more potent than VIP in providing neuroprotection. Neuronal survival was assessed in rat cerebral critical cultures. A cGMP antagonist (RP-8-pCPT-cGMPS, 10(-12)-10(-9) M) reduced the number of surviving neurons (40-60%), this decline was spared in the presence of SNV (10(-13) M). A cGMP agonist (Sp-8-pCPT-cGMPS, 10(-14)-10(-8) M) and SNV (10(-16)-10(-8) M) both provided significant neuroprotection against 10(-12) M of the cGMP antagonist. Immunoassays indicated that SNV induced increases in cGMP (two-threefold) in these cultures, whereas VIP was 1000-fold less potent. These results implicate cGMP as a second messenger for VIP/SNV-mediated effects on neuronal survival. (C) 1999 Elsevier Science Inc. All rights reserved.

引用

收藏

页码：629 / 633

页数：5

相关论文

共 23 条

[1] Development of high affinity selective VIP1 receptor agonists [J].

Gourlet, P ;

Vandermeers, A ;

Vertongen, P ;

Rathe, J ;

De Neef, P ;

Cnudde, J ;

Waelbroeck, M ;

Robberecht, P .

PEPTIDES, 1997, 18 (10) :1539-1545

[2] VIP - MOLECULAR-BIOLOGY AND NEUROBIOLOGICAL FUNCTION [J].

GOZES, I ;

BRENNEMAN, DE .

MOLECULAR NEUROBIOLOGY, 1989, 3 (04) :201-236

[3] A FATTY NEUROPEPTIDE - POTENTIAL-DRUG FOR NONINVASIVE IMPOTENCE TREATMENT IN A RAT MODEL [J].

GOZES, I ;

FRIDKIN, M .

JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (03) :810-814

[4]

Gozes I, 1997, J NEUROBIOL, V33, P329, DOI 10.1002/(SICI)1097-4695(199709)33:3<329::AID-NEU10>3.0.CO

[5]

2-A

[6] Antiserum to activity-dependent neurotrophic factor produces neuronal cell death in CNS cultures: Immunological and biological specificity [J].

Gozes, I ;

Davidson, A ;

Gozes, Y ;

Mascolo, R ;

Barth, R ;

Warren, D ;

Hauser, J ;

Brenneman, DE .

DEVELOPMENTAL BRAIN RESEARCH, 1997, 99 (02) :167-175

[7]

GOZES I, 1995, J PHARMACOL EXP THER, V273, P161

[8] Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide [J].

Gozes, I ;

Bardea, A ;

Reshef, A ;

Zamostiano, R ;

Zhukovsky, S ;

Rubinraut, S ;

Fridkin, M ;

Brenneman, DE .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (01) :427-432

[9] STEARYL-NORLEUCINE-VASOACTIVE INTESTINAL PEPTIDE (VIP) - A NOVEL VIP ANALOG FOR NONINVASIVE IMPOTENCE TREATMENT [J].

GOZES, I ;

RESHEF, A ;

SALAH, D ;

RUBINRAUT, S ;

FRIDKIN, M .

ENDOCRINOLOGY, 1994, 134 (05) :2121-2125

[10]

GOZES I, 1991, J PHARMACOL EXP THER, V257, P959